MAM
TXMD icon

Meeder Asset Management’s TherapeuticsMD TXMD Stock Holding History

Meeder Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Hold
0
– – – 2641
2021
Q2 		– Hold
0
– – – 2666
2021
Q1 		– Hold
0
– – – 2462
2018
Q1 		– Sell
-2
Closed -$1K – 1753
2017
Q4 		$1K Buy
+2
New +$557 ﹤0.01% 1596
2017
Q2 		– Sell
-37
Closed -$13K – 1880
2017
Q1 		$13K Buy
+37
New +$11.4K ﹤0.01% 800

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Meeder Asset Management's TXMD Position: Q3 2021 in Review

Meeder Asset Management held its TherapeuticsMD (TXMD) position steady in Q3 2021 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2641.

Meeder Asset Management first reported a position in TXMD in Q1 2017 and has held it in 2 quarters since. The position peaked at $13K in Q1 2017. 149 funds tracked by Wall St. Rank hold TXMD as of Q3 2021.

  • Meeder Asset Management held 0 shares of TherapeuticsMD worth $0 as of Q3 2021.
  • Meeder Asset Management left its TherapeuticsMD share count unchanged in Q3 2021.
  • TherapeuticsMD made up ﹤0.01% of Meeder Asset Management's portfolio in Q3 2021, its #2641 holding.
  • Meeder Asset Management first reported a position in TherapeuticsMD in Q1 2017 and has held it in 2 quarters since.
  • Meeder Asset Management's TherapeuticsMD position peaked at $13K in Q1 2017.
  • 149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2021.

Based on Meeder Asset Management's 13F filing for Q3 2021, filed 8 Nov 2021.